Test Catalog

Take Our Survey

Test ID: NPAIN    
Pain Clinic Drug Screen, Urine

Useful For Suggests clinical disorders or settings where the test may be helpful

Detection and identification of drugs of abuse


This test is intended to be used in a setting where the identification of the drug is required.

Testing Algorithm Delineates situation(s) when tests are added to the initial order. This includes reflex and additional tests.

Testing begins with screening tests for alcohol and drugs of abuse. Positives are confirmed and quantitated by definitive methods. Gas chromatography-mass spectrometry for amphetamines, barbiturates, benzodiazepines, cocaine and metabolites, phencyclidine, and tetrahydrocannabinol metabolite at an additional charge. Methadone and opiates that screen positive will be quantified with liquid chromatography-tandem mass spectrometry at an additional charge.  


See Adulterant Survey Algorithm in Special Instructions.

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

This profile was designed to test for and confirm the most common classes of drugs of abuse.


Opiate confirmation is performed on all specimens by liquid chromatography-tandem mass spectrometry (LC-MS/MS). 


This profile uses immunoassay testing for drugs of abuse by class. All positive screening results are confirmed by gas chromatography/mass spectrometry or LC-MS/MS.

Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

Negative for drugs of abuse



Enzyme-multiplied immunoassay technique screening cutoff concentration:

Amphetamines: 500 ng/mL

Barbiturates: 200 ng/mL

Benzodiazepines: 200 ng/mL

Cocaine (benzoylecgonine-cocaine metabolite): 150 ng/mL

Ethanol: 10 mg/dL

Methadone: 300 ng/mL

Opiates: 300 ng/mL

Phencyclidine: 25 ng/mL

Tetrahydrocannabinol carboxylic acid: 50 ng/mL



Positive cutoff concentrations

Codeine: <100 ng/mL

Hydrocodone: <100 ng/mL

Hydromorphone: <100 ng/mL

Morphine: <100 ng/mL

Oxycodone: <100 ng/mL

Oxymorphone: <100 ng/mL



This report is intended for use in clinical monitoring and management of patients. It is not intended for use in employment-related drug testing.

Interpretation Provides information to assist in interpretation of the test results

A positive result derived by this testing indicates that the patient has been exposed in the recent past to the drugs identified.


Positive results are definitive.


A detailed discussion of each drug detected is beyond the scope of this text. Each report will indicate the drugs identified. If a clinical interpretation is required, contact Mayo Medical Laboratories at 800-533-1710.

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

This report is intended for use in clinical monitoring and management of patients. It is not intended for use in employment-related drug testing.

Clinical Reference Provides recommendations for further in-depth reading of a clinical nature

1. Goodman and Gilman's: The Pharmacological Basis of Therapeutics. 10th edition. New York, McGraw-Hill Professional, 2001

2. Porter WF: Clinical toxicology. In Teitz Textbook of Clinical Chemistry and Molecular Diagnostics. Fourth edition. St Louis, MO, Elsevier Saunders, 2006

3. Principles of Forensic Toxicology. Second edition. Washington DC, AACC Press, 2003, p 385

Special Instructions and Forms Describes specimen collection and preparation information, test algorithms, and other information pertinent to test. Also includes pertinent information and consent forms to be used when requesting a particular test